Randomized Study of Obicetrapib in Combination With Ezetimibe

Summary

This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.

Timeline

Start

2021-02-23

Primary completion

2021-05-07

Completion

2021-06-30

Outcome

Met primary endpoint

registry MEAN Combination Therapy: -45.63 (Standard Deviation 21.677) percent change from baseline NCT04770389 ↗

registry analysis (superiority test); Combination Therapy vs Placebo; p <0.0001; Least Squares (LS) Mean -44.92 (95% CI -55.20 to -34.63); Mixed Models Analysis NCT04770389 ↗

Publications

• Pirillo A, Catapano AL. The two faces of cholesteryl ester transfer protein inhibitors. Curr Opin Lipidol. 2025 Dec 1;36(6):318-325. doi: 10.1097/MOL.0000000000001017. Epub 2025 Oct 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ezetimibe	Unknown	10 mg	—
Subject	Obicetrapib	Small molecule	5 mg	—

Indications